文献リスト

1) Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007; 7: 673-83

2) Jaffe ES, Harris NL, Stein H, et al. In: World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001

3) Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007; 109: 4924-9

4) Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008; 93: 1635-44

5) Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007; 21: 505-10

6) Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006; 107: 176-83

7) Fridman J, Nussenzveig R, Liu P, et al. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. ASH annual meeting abstracts. 2007; 110: abstract 3538

8) Verstovsek S, Pardanani AD, Shah NP, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. ASH annual meeting abstracts. 2007; 110: abstract 553

9) Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008; 13: 311-20

10) Verstovsek S, Kantarjian HM, Pardanani AD, et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ET MF). ASH annual meeting abstracts. 2008; 112: abstract 1762

11) Verstovsek S, Kantarjian HM, Pardanani AD, et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F: WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB018424. ASH annual meeting abstracts. 2008; 112: abstract 2802

12) Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. ASH annual meeting abstracts. 2008; 112: abstract 98

13) Pardanani AD, Gotlib J, Jamieson C, et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. ASH annual meeting abstracts. 2008; 112: abstract 97

14) Pardanani A, Lasho T, Burns CJ, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectively and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009; 23: 1441-5

15) Nussenzveig RH, Cortes J, Sever M, et al. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009; 90: 58-63

16) Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid disease, including systemic mastocytosis. Clin Cancer Res. 2008; 14: 3906-15

17) Dobrzanski P, Hexner E, Serdikoff C, et al. CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. ASH annual meeting abstracts. 2006; 108: abstract 3594

18) Goh KC, Ong WC, Hu C, et al. SB1518: a potent and orally active JAK2 inhibitor for treatment of myeloproliferative disorders. ASH annual meeting abstracts. 2007; 110: abstract 538

19) Moliterno AR, Roboz GJ, Carroll M, et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. ASH annual meeting abstracts. 2008; 112: abstract 99

20) Tibes R, Giles F, McQueen T, et al. Translational in vivo and in vitro studies in patients (pts) with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myeloproliferative disease (MPD) treated with MK-0457 (MK), a novel Aurora kinase, Flt3, JAK2, and Bcr-Abl inhibitor. ASH annual meeting abstracts. 2006; 108: abstract 1362

21) Lyons J, Curry J, Mallet K, et al. JAK2 and T315I Abl activity of clinical candidate, AT9283. 98th AACR annual meeting. 2007: abstract 5747

22) Giles F, Bergstrom DA, Gacia-Manero G, et al. MK-0457 is a novel Auroa kinase and Janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). ASH annual meeting abstracts. 2006; 108: abstract 4893

23) Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofirosis with myeloid metaplasia. Blood. 2006; 108: 1158-64

24) Quintás-Cardama A, Tefferi A, Thomas D, et al. Phase II study of lenalidomide and prednisone for patients with myelofibrosis. ASH annual meeting abstracts. 2007; 110: abstraxt 3545

25) Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofirosis. J Clin Oncol. Published ahead of print on Aug 3, 2009

26) Larghero J, Gervais N, Cassinat B, et al. Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood. 2005; 105: 3743-5

27) Mesa RA, Camoriano JK, Geyer SM, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007; 21: 1964-70

28) Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia. 2008; 22: 740-7

29) Guerini V, Spinelli O, Sc B, et al. Potent inhibition of EEC colony formation in JAK2V617F PV and ET by low doses of ITF2357, a new histone deacetylase inhibitor. ASH annual metting abstracts. 2006; 108: abstract 2702

30) Rambaldi A, Maria Dellacasa C, Salmoiraghi S, et al. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with JAK2V617F positive chronic myeloproliferative neoplasms. ASH annual meeting abstracts. 2008; 112: abstract 100

31) Jedidi A, Marty C, Oligo C, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood. prepublished online July 9, 2009

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp